A GLP-1 drug called orforglipron—taken in pill form once a day—has been shown to help with “significant” weight loss in people with obesity. In a multinational trial of around 3,000 adults, a 72-week ...

A sweeping review of dozens of clinical trials suggests that today’s most widely used GLP-1 receptor agonist drugs produce broadly consistent weight-loss results across age, race, ethnicity, and ...

The treatment, known as CagriSema, combines two hormone-based drugs — semaglutide, already approved for weight loss, and cagrilintide, which is still being studied. Cagrilintide is a long-acting form ...

GLP-1 receptor agonists have gained attention as medications to manage type 2 diabetes and obesity. Drugs such as semaglutide and tirzepatide help regulate blood sugar and reduce appetite, which can ...

Analysis of a large unsubsidized digital weight-loss service reveals that consistent treatment adherence and active engagement, not access alone, are the key factors separating modest results from ...